Parker Geoffrey M.
SEC-identified person · CIK 1491874 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Perrigo Co plc PRGO | Director | filed 2016 - 2026 |
| Allogene Therapeutics, Inc. ALLO | CHIEF FINANCIAL OFFICER | filed 2023 - 2026 |
| Mountain Crest Acquisition Corp II MCADU | Director | filed 2021 - 2023 |
| Chemocentryx, Inc. CCXI | Director | filed 2012 - 2022 |
| Tricida, Inc. TCDA | Chief Fin. Officer and Sr. VP | filed 2018 - 2022 |
| Genomic Health INC GHDX | Director | filed 2016 - 2019 |
| Viracta Therapeutics, Inc. VIRX | Director | filed 2016 - 2017 |
| Anacor Pharmaceuticals, Inc. ANAC | Sr. V.P. & CFO | filed 2010 - 2015 |
| Genoptix INC GXDX | Director | filed 2010 - 2011 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.